CAR T cells are engineered to target plasma cells and have received FDA approval. These therapies demonstrate sustained responses, especially in refractory multiple myeloma. While there is potential for cures in newly diagnosed patients, long-term disease-free rates are low. Upfront CAR T cell implementation may enhance remission, but managing side effects is crucial. The future looks promising, pending more data.